Cargando…
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells
Gemcitabine (GEM) is the front-line standard chemotherapy used for the treatment of pancreatic cancer; however, chemoresistance to GEM remains the major obstacle to the successful control of this disease. Both the expression levels and activity of aldehyde dehydrogenase 1A1 (ALDH1A1) are important f...
Autores principales: | DUONG, HONG-QUAN, HWANG, JAE SEOK, KIM, HEE JEONG, KANG, HYO JIN, SEONG, YEON-SUN, BAE, INSOO |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508685/ https://www.ncbi.nlm.nih.gov/pubmed/22710732 http://dx.doi.org/10.3892/ijo.2012.1516 |
Ejemplares similares
-
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2014) -
Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo
por: Chen, Ya-Hui, et al.
Publicado: (2020) -
AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2
por: Fahy, B N, et al.
Publicado: (2003) -
Role of Intracellular and Extracellular Annexin A1 in MIA PaCa-2 Spheroids Formation and Drug Sensitivity
por: Novizio, Nunzia, et al.
Publicado: (2022) -
MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors
por: Gradiz, Rui, et al.
Publicado: (2016)